RAMM Pharma Corp.
RAMM
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 156.80K | 436.50K | 642.90K | 606.20K | 710.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.80K | 436.50K | 642.90K | 606.20K | 710.80K |
| Cost of Revenue | 56.60K | 95.60K | 642.50K | 499.20K | 553.90K |
| Gross Profit | 100.30K | 340.90K | 300.00 | 107.00K | 156.90K |
| SG&A Expenses | 789.80K | 1.39M | 687.40K | 695.40K | 1.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.10K | 45.90K | 3.30K | 5.20K | 3.70K |
| Total Operating Expenses | 847.50K | 1.53M | 1.33M | 1.20M | 1.57M |
| Operating Income | -690.60K | -1.09M | -690.40K | -593.60K | -859.30K |
| Income Before Tax | -559.20K | -5.15M | -380.70K | -79.90K | -782.30K |
| Income Tax Expenses | -- | 7.70K | -- | 66.00K | -62.80K |
| Earnings from Continuing Operations | -559.20K | -5.16M | -380.70K | -145.90K | -719.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -559.20K | -5.16M | -380.70K | -145.90K | -719.50K |
| EBIT | -690.60K | -1.09M | -690.40K | -593.60K | -859.30K |
| EBITDA | -613.40K | -1.02M | -592.30K | -467.90K | -689.50K |
| EPS Basic | 0.00 | -0.04 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.04 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Average Diluted Shares Outstanding | 119.39M | 119.39M | 119.39M | 119.39M | 119.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |